Seclin

Researchers are evaluating the effects of caffeine on cognitive decline in people with Alzheimer's disease at the beginning to moderate stages. This phase 3 trial aims to compare the impact of caffeine treatment versus placebo on cognition over 30 weeks. Alzheimer’s disease is a complex condition with no current cure, and caffeine's properties may offer symptomatic benefits, although high doses could cause anxiety and insomnia, especially in this vulnerable group. Participants will undergo a 6-week caffeine diet before starting treatment. Then, caffeine or placebo capsules will be given with a titration phase of 3 weeks increasing the dose by 100mg every stage until reaching a target of 400mg daily in two doses, maintained for 27 weeks. After treatment, doses will be gradually decreased following the same schedule. During the study, participants will be monitored for changes in cognitive function measured by neuropsychological tests at 30 weeks after randomization. Caregivers will be involved, and participants’ clinical status, safety, and adherence to a low caffeine diet will be assessed. The total participation duration includes the caffeine diet, titration, treatment, and dose reduction phases.

There is a wide variation in how rapid sequence induction is performed in operating rooms worldwide. This study aims to describe how French anesthesiologists prevent serious blood flow problems during rapid sequence anesthetic induction in adult patients. It focuses on the occurrence of major hemodynamic disorders, such as low or high blood pressure, sustained arrhythmias, or cardiac arrest within the first 10 minutes after anesthesia begins. Participants will undergo rapid sequence anesthetic induction, a process used to quickly induce general anesthesia for patients at high risk of lung fluid aspiration. The study will observe the clinical practices of pre-oxygenation, induction, and intubation, and check how well these practices follow the formal expert recommendations from 2017 and 2018. Data on the prevention of gastric fluid inhalation, equipment used, drugs administered, and clinical parameters will be collected during the induction process. Throughout the study, researchers will monitor neurological and cardio-respiratory signs and record any complications within the first 10 minutes after anesthesia induction. The main outcome measured is the occurrence of major hemodynamic disorders during this period. The study is observational and multicenter, involving adult patients undergoing rapid sequence induction in France.

Chronic obstructive pulmonary disease (COPD) is a long-lasting inflammatory disease of the airways often caused by environmental factors. This condition frequently worsens with acute flare-ups known as exacerbations, which significantly affect patients' health and survival. Nearly half of these flare-ups are linked to bacterial infections, and patients with COPD often have bacteria in their airways that increase their risk of infection. Researchers are investigating whether a weakened immune response involving IL-17 and IL-22 contributes to these bacterial problems in COPD. Participants in this study will have samples collected during a COPD flare-up and again in a stable state 8 to 16 weeks later. These samples include sputum, blood, and a swab from the upper throat. Lung function will also be measured and tracked over a period of four years to understand changes over time. The study focuses on examining the immune response to bacteria during these different phases of the disease. Throughout the study, researchers will measure specific immune proteins called cytokines using blood tests at the time of flare-up and during the stable phase. They will also monitor lung function regularly over four years to assess disease progression. This long-term follow-up helps to better understand how the immune response affects bacterial infections and COPD exacerbations.

Gambling disorder (GD) is recognized as an addictive disorder characterized by craving, which can lead to relapse. This research evaluates the effectiveness of Virtual Reality Exposure Therapy (VRET) combined with Cognitive-Behavioral Therapy (CBT) compared to imaginal exposure therapy combined with CBT in treating GD. The study is a multicenter, randomized, controlled, non-inferiority clinical trial aiming to show that VRET is not less effective than imaginal exposure therapy in reducing GD symptoms. Participants will receive 12 treatment sessions, with 6 sessions focused on CBT and either 6 sessions of VRET or imaginal exposure therapy targeting gambling cues. VRET uses a virtual gambling environment to expose patients to triggers in a controlled way, while imaginal exposure involves mentally confronting gambling cues. Both therapies aim to reduce craving and gambling behaviors. During the study, researchers will assess changes in gambling severity using the South Oaks Gambling Screen (SOGS) at baseline and after treatment. They will also evaluate gambling behavior, craving, gambling-related thoughts, anxiety, depression, and treatment quality up to 12 months post-treatment. Participants will be monitored for adherence and outcomes throughout the study period.